Stockscreener 앱 받기
4.57
12.29%
0.50
시간 외 거래:
4.57
전일 마감가:
$4.07
열려 있는:
$4.45
하루 거래량:
776.19K
Relative Volume:
4.84
시가총액:
$40.31M
수익:
-
순이익/손실:
$-20.74M
주가수익비율:
-1.8207
EPS:
-2.51
순현금흐름:
$-18.90M
1주 성능:
+111.57%
1개월 성능:
+131.98%
6개월 성능:
+69.89%
1년 성능:
+73.11%
1일 변동 폭
$4.4212
$4.8918
1주일 범위
$3.98
$4.8918
52주 변동 폭
$1.81
$4.8918
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
LSTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
4.57 | 35.90M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - Stock Titan
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital | LST - GuruFocus
Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs - Intellectia AI
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Asianet Newsable
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz
Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $36.7 million. - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Why Is Lisata Therapeutics Stock Gaining Today? - Benzinga
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - Benzinga
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson... - Proactive financial news
Lisata stock soars after Kuva Labs acquisition offer at 85% premium By Investing.com - Investing.com South Africa
Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Nigeria
Lisata Therapeutics Signs Binding Term Sheet With Kuva Labs - TradingView
Lisata To Be Acquired By Kuva Labs For $4/shr; Stock Soars Over 80% - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs for $4 per Share - Intellectia AI
Lisata Therapeutics (LSTA) Agrees to Acquisition by Kuva Labs - GuruFocus
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer - marketscreener.com
Kuva Labs to acquire Lisata Therapeutics for $4 per share - Investing.com
Lisata Therapeutics To Be Acquired By Kuva Labs For $4.00 Per Share In An All-Cash Tender Offer - TradingView
Lisata Therapeutics Enters Into Term Sheet to be Acquired - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
How Lisata Therapeutics Inc. (8NE) stock compares with top peersVolatility Index Analysis & Budget Friendly Growth - bollywoodhelpline.com
Aug Highlights: Will Lisata Therapeutics Inc stock benefit from M A - baoquankhu1.vn
Aug Closing: What is Lisata Therapeutics Incs market positionPortfolio Return Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Macro Review: How Lisata Therapeutics Inc. (8NE) stock compares with top peers2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
How Lisata Therapeutics Inc. (8NE) stock benefits from digital adoptionDollar Strength & High Win Rate Trade Alerts - ulpravda.ru
Why Lisata Therapeutics Inc. stock could benefit from AI revolutionMid Cap Growth Trends & Investment Portfolio Recommendations - Улправда
Lisata Ahead Of The Curve: Smart Partnerships, No Debt, And A Data-Rich Period Ahead - RTTNews
Lisata Therapeutics Q3 2025 Earnings Preview - MSN
Retail Trends: Can Lisata Therapeutics Inc 8NE stock deliver consistent EPS growth2025 Retail Activity & Daily Volume Surge Signals - moha.gov.vn
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):